Table 1.

Select agents targeting amino acid metabolism that are developed, in trials or in the clinic, for the treatment of cancer.

Enzyme/ transporter	Inhibitor	Phase (status)	Cancer type
IDO1	BMS-986205 Navoximod (NLG-919) Pembrolizumab (in combination trial with epacadostat) PF-06840003	Phase I/II Phase I Phase II/III Phase II/III	Advanced cancer, melanoma, NSCLC Solid tumors RCC, melanoma, head and neck, gastro, malignant solid tumor, NSCLC, neoplasma (Phase I) Oligodendroglioma, astrocytoma, malignant glioma
IDO and TDO	HTI-1090 (dual inhibitor)	Phase I	Advanced solid tumors
GLS	CB-839 + cabozantinib CB-839 + talazoparib CB-839 + nivolumab CB-839 hydrochloride + osimertinib CB-839 + panitumumab, irinoteca hydrochloride CB-839 + azacytidine CB-839 + capecitabine CB-839 + palbociclib	Phase II Phase Ib/II Phase I/II Phase I/II Phase I/II Phase I/II Phase I/II Phase Ib/II	Renal cell carcinoma Solid tumors Melanoma, ccRCC, NSCLC Mutated stage iv NSCLC Metastatic and refractory RAS wildtype colorectal Advanced myelodysplastic syndrome Advanced solid tumors, colorectal cancer Solid tumors
ASCT2	V-9302		In vivo mouse models and in vitro
xCT	Sorafenib PRLX 93936 (erastin analog)	In clinic Phase I	Kidney, liver, and thyroid cancer Solid tumors
PHGDH	NCT-502 NCT-503		In vitro In vitro and mouse
GOT/AST	Aspulvinone O		Mouse
LAT1	JPH203		In vitro